In patients with symptomatic BPH, the best IPSS result was a 4-point improvement in excess of placebo, with cetrorelix pamoate 60 mg followed by 30 mg 2 weeks later.
In plain wordsIn patients with BPH, a 60 mg then 30 mg cetrorelix pamoate regimen improved urinary symptom scores by 4 points more than placebo.
- Peptide
- Cetrorelix
- Outcome
- Direction not reportedIPSS
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Urinary continence and bladder function · Kidney and urinary
- Studied dose
- 60 mg followed by 30 mg 2 weeks later · IntramuscularAs given in this study (human).
Measurements
- IPSS improvement beyond placebo
- 4 points
- cetrorelix pamoate 60 mg then 30 mg versus placebo
Source sentences
Optimal results, a 4-point improvement in IPSS in excess of the changes observed in the placebo group, were achieved with a starting dose of 60 mg cetrorelix pamoate followed by a dose of 30 mg 2 weeks later.
4 context sentences(design, population, supporting numbers)
A statistically significant overall difference was found with respect to the primary variable, the IPSS (P ≤ .001).
Double-blind, randomized, multicenter study was undertaken among patients with International Prostate Symptom Score (IPSS) ≥ 13.
After a single-blind placebo run-in phase of 4 weeks, treatment was administered at 2-week intervals as follows: 30 + 30 mg, 30 + 30 + 30 mg, 60 + 30, 60 + 60 mg cetrorelix pamoate, or matching placebo.
Intramuscular injections of 60 and 30 mg of cetrorelix pamoate within 2 weeks provide rapid symptomatic improvements of BPH that are sustained for the following 6 months.